Soligenix Completes Interim Phase 3 Efficacy Analysis for HyBryte CTCL Treatment

Key Facts

Soligenix, Inc. has announced a significant milestone in its clinical development program, as the Data Monitoring Committee completed the interim efficacy analysis for the pivotal Phase 3 FLASH2 trial. The study evaluates the efficacy of HyBryte in patients suffering from cutaneous T-cell lymphoma (CTCL), a rare form of cancer with limited treatment options. This interim analysis serves as a critical step in validating the therapeutic potential of the drug before proceeding toward final regulatory milestones. The company remains focused on addressing significant unmet medical needs within the rare disease landscape. Market participants are closely watching these developments, as positive clinical trial progress often drives speculative interest in micro-cap biotechnology firms. Further disclosure of the full data set is expected to provide more clarity on the commercial viability of the treatment.